Paula Pohlmann
Overview
Explore the profile of Paula Pohlmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
178
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shatsky R, Trivedi M, Yau C, Nanda R, Rugo H, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3737-3747.
PMID: 39277672
Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity. Here we describe the results of incorporating a promising antibody-drug conjugate, datopotamab-deruxtecan...
2.
Khoury K, Meisel J, Yau C, Rugo H, Nanda R, Davidian M, et al.
Nat Med
. 2024 Sep;
30(12):3728-3736.
PMID: 39277671
Among the goals of patient-centric care are the advancement of effective personalized treatment, while minimizing toxicity. The phase 2 I-SPY2.2 trial uses a neoadjuvant sequential therapy approach in breast cancer...
3.
Piha-Paul S, Olwill S, Hamilton E, Tolcher A, Pohlmann P, Liu S, et al.
Clin Cancer Res
. 2024 Sep;
31(2):288-298.
PMID: 39235868
Purpose: 4-1BB (CD137) is a costimulatory immune receptor expressed on activated T cells, activated B cells, NK cells, and tumor-infiltrating lymphocytes, making it a promising target for cancer immunotherapy. Cinrebafusp...
4.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
Nat Commun
. 2024 May;
15(1):3957.
PMID: 38730268
No abstract available.
5.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
Nat Commun
. 2024 Mar;
15(1):2691.
PMID: 38538574
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the...
6.
Magbanua M, Ahmed Z, Sayaman R, Swigart L, Hirst G, Yau C, et al.
Clin Cancer Res
. 2024 Mar;
30(11):2444-2451.
PMID: 38470545
Purpose: We previously demonstrated the clinical significance of circulating tumor DNA (ctDNA) in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy (NAC). Here, we compared its predictive and prognostic value...
7.
Wang H, Yee D, Potter D, Jewett P, Yau C, Beckwith H, et al.
Breast Cancer Res Treat
. 2024 Jan;
204(3):589-597.
PMID: 38216819
Purpose: Increased body mass index (BMI) has been associated with poor outcomes in women with breast cancer. We evaluated the association between BMI and pathological complete response (pCR) in the...
8.
Lynce F, Mainor C, Donahue R, Geng X, Jones G, Schlam I, et al.
medRxiv
. 2023 Dec;
PMID: 38105958
Chemotherapy and immune checkpoint inhibitors have a role in the post-neoadjuvant setting in patients with triple-negative breast cancer (TNBC). However, the effects of nivolumab, a checkpoint inhibitor, capecitabine, or the...
9.
Nakamura Y, Mizuno N, Sunakawa Y, Canon J, Galsky M, Hamilton E, et al.
J Clin Oncol
. 2023 Sep;
41(36):5569-5578.
PMID: 37751561
Purpose: To evaluate the efficacy and safety of tucatinib and trastuzumab in patients with previously treated human epidermal growth factor receptor 2-positive (HER2+) metastatic biliary tract cancer (mBTC). Methods: SGNTUC-019...
10.
Wang H, Yee D, Potter D, Jewett P, Yau C, Beckwith H, et al.
Res Sq
. 2023 Jul;
PMID: 37397981
Purpose: Increased body mass index (BMI) has been associated with poor outcomes in women with breast cancer. We evaluated the association between BMI and pathological complete response (pCR) in the...